In vitro evidence of oncofetal antigen and TLR-9 agonist co-delivery by alginate nanovaccines for liver cancer immunotherapy. (21st April 2022)

• Record Type: Journal Article
• Authors: Pei, Mengyue; Li, Huiyang; Zhu, Yingwei; Lu, Jian; Zhang, Chuangnian
• Is Part Of: Biomaterials science. Volume 10:Number 11(2022)
• Page Start: 2865
• Page End: 2876
• Publication Date: 2022-04-21
• Subjects: Biomedical materials -- Periodicals; 610.28
• DOI: 10.1039/d1bm02021h
• Languages: English
• ISSNs: 2047-4830

Abstract

Abstract : Antigen and adjuvant co-delivery nanovaccines were prepared to induce antigen-specific antitumor immune responses against liver cancer. Abstract : Liver cancer is the most common malignant tumor and liver cancer immunotherapy has been one of the research hotspots. To induce antigen-specific antitumor immune responses against liver cancer, we developed antigen and adjuvant co-delivery nanovaccines (APPCs). Polyanionic alginate (ALG) and polycationic polyethyleneimine (PEI) were utilized to co-deliver a glypican-3 peptide antigen and an unmethylated cytosine-phosphate-guanine (CpG) adjuvant by electrostatic interactions. A cellular uptake study confirmed that APPC could promote antigen and adjuvant uptake by dendritic cells (DCs). Importantly, APPC facilitated the endosomal escape of the peptide for antigen delivery into the cytoplasm. In addition, APPC showed significant stimulation of DC maturation in vitro . APPC could also efficiently prime DCs and induce cytotoxic T lymphocyte responses in vivo . The in vitro cell viability assay and the in vivo histocompatibility showed that APPC was non-toxic within the tested concentration. This study demonstrates that the peptide antigen and the CpG adjuvant co-delivery nanovaccine have potential applications in liver cancer immunotherapy.